Change of heart and mind: Autism’s ties to cardiac defects
Children with congenital heart disease have an increased likelihood of autism. Why?
Children with congenital heart disease have an increased likelihood of autism. Why?
This month’s issue of the Null and Noteworthy newsletter breaks down some negative results involving prenatal exposures, an experimental treatment for Angelman syndrome, and the role that age at autism diagnosis plays in subsequent outcomes, and more.
Contrary to conventional wisdom, most people with fragile X syndrome express the FMR1 gene — albeit improperly.
This month’s newsletter looks at the early safety data from the first gene therapy trial for Rett syndrome, among other drug development news.
The gene-editing advances make it easier to target specific tissues in mice and detect off-target effects.
In this episode of “Synaptic,” Kasari talks about the need for inclusion in educating autistic children, what drew her into the autism research field, and growing up on the family farm.
This month’s issue of Going on Trial takes a sneak peek at some early null results from a small trial of a cannabidiol-based drug for autism, among other recent drug developments.
Experiments offer clues to why certain mutations are associated with autism in some people and not others.
Autistic toddlers who receive a personalized intervention at about 18 months of age gain more abilities than those who start the therapy nine months later.
Autistic children taking the drug showed improvements in some behaviors but not in their social skills.